+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Regeneron Pharmaceuticals Inc (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc Key Recent Developments

  • Mar 29, 2023: Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies
  • Feb 03, 2023: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
  • Nov 18, 2022: Regeneron, CytomX partner to develop bispecific cancer therapies
  • Nov 03, 2022: Regeneron presents new data at ASH from advancing hematology pipeline across multiple blood cancers and disorders

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Regeneron Pharmaceuticals Inc - Key Facts
  • Regeneron Pharmaceuticals Inc - Key Employees
  • Regeneron Pharmaceuticals Inc - Key Employee Biographies
  • Regeneron Pharmaceuticals Inc - Major Products and Services
  • Regeneron Pharmaceuticals Inc - History
  • Regeneron Pharmaceuticals Inc - Company Statement
  • Regeneron Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Business Unit
Section 2 - Company Analysis
  • Company Overview
  • Regeneron Pharmaceuticals Inc - Business Description
  • Product Category: Arcalyst
  • Overview
  • Performance
  • Product Category: Collaboration Revenue
  • Overview
  • Performance
  • Product Category: Evkeeza
  • Overview
  • Performance
  • Product Category: Eylea
  • Overview
  • Performance
  • Product Category: Inmazeb
  • Overview
  • Performance
  • Product Category: Libtayo
  • Overview
  • Performance
  • Product Category: Other Revenue
  • Performance
  • Product Category: Praluent
  • Overview
  • Performance
  • Product Category: Regen-COV
  • Overview
  • Performance
  • R&D Overview
  • Regeneron Pharmaceuticals Inc - Corporate Strategy
  • Regeneron Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Regeneron Pharmaceuticals Inc - Strengths
  • Regeneron Pharmaceuticals Inc - Weaknesses
  • Regeneron Pharmaceuticals Inc - Opportunities
  • Regeneron Pharmaceuticals Inc - Threats
  • Regeneron Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Regeneron Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 29, 2023: Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies
  • Feb 03, 2023: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
  • Nov 18, 2022: Regeneron, CytomX partner to develop bispecific cancer therapies
  • Nov 03, 2022: Regeneron presents new data at ASH from advancing hematology pipeline across multiple blood cancers and disorders
  • Nov 03, 2022: Regeneron reports third quarter 2022 financial and operating results
  • Oct 03, 2022: Regeneron Elects Dr. Craig B. Thompson to Board of Directors
  • Sep 08, 2022: OncoResponse and Regeneron enter cancer therapy clinical supply agreement
  • Aug 25, 2022: Regeneron Announces Investor Conference Presentations
  • Aug 03, 2022: Regeneron Reports Second Quarter 2022 Financial and Operating Results
  • Jul 27, 2022: Regeneron Genetics Center discovers rare mutations in the CIDEB gene that protect against liver disease
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Regeneron Pharmaceuticals Inc, Key Facts
  • Regeneron Pharmaceuticals Inc, Key Employees
  • Regeneron Pharmaceuticals Inc, Key Employee Biographies
  • Regeneron Pharmaceuticals Inc, Major Products and Services
  • Regeneron Pharmaceuticals Inc, History
  • Regeneron Pharmaceuticals Inc, Other Locations
  • Regeneron Pharmaceuticals Inc, Subsidiaries
  • Regeneron Pharmaceuticals Inc, Business Unit
  • Regeneron Pharmaceuticals Inc, Key Competitors
  • Regeneron Pharmaceuticals Inc, Ratios based on current share price
  • Regeneron Pharmaceuticals Inc, Annual Ratios
  • Regeneron Pharmaceuticals Inc, Interim Ratios
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Regeneron Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Regeneron Pharmaceuticals Inc, Performance Chart (2018 - 2022)
  • Regeneron Pharmaceuticals Inc, Ratio Charts
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Xbrane Biopharma AB
  • Torii Pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • Stada Arzneimittel AG
  • Sanofi
  • Samsung Bioepis Co Ltd
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Maruho Co Ltd
  • LEO Pharma Inc
  • Japan Tobacco Inc
  • Incyte Corp
  • GSK plc
  • Gilead Sciences Inc
  • Genentech USA Inc
  • Galapagos NV
  • Formycon AG
  • Eli Lilly and Co
  • Coherus BioSciences Inc
  • Chugai Pharmaceutical Co Ltd
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • Bioeq IP AG
  • Bayer AG
  • Bausch + Lomb Corp
  • AstraZeneca Plc
  • Amgen Inc
  • Allergan Inc
  • Alimera Sciences Inc
  • AbbVie Inc
  • AstraZeneca Plc
  • AbbVie Inc
  • Alimera Sciences Inc
  • Teva Pharmaceutical Industries Ltd
  • Chugai Pharmaceutical Co Ltd
  • LEO Pharma Inc
  • GSK plc
  • Bristol-Myers Squibb Co
  • Incyte Corp
  • Pfenex Inc
  • Sanofi
  • Allergan Inc
  • Pfizer Inc
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Japan Tobacco Inc
  • Gilead Sciences Inc
  • Novartis AG
  • Merck & Co Inc
  • Genentech USA Inc
  • Bayer AG
  • Samsung Bioepis Co Ltd
  • Amgen Inc
  • Eli Lilly and Co